KESTRA MEDICAL TECHNOLOGIES, LTD. 1Q 2027: Revenue $30.97M, EPS $(0.75) — 10-Q Summary

Kestra Medical Technologies reported Q1 2027 revenue of $30.97M, up 60% YoY, but a net loss of $(44.09)M. Diluted EPS was $(0.75). Growth was driven by increased use of its ASSURE® wearable cardiac defibrillator, with revenue primarily from Medicare, Medicaid, and private payors. The company expanded sales and marketing and improved operational efficiency.

Original reporting
Published Sep 14, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
KESTRA MEDICAL TECHNOLOGIES, LTD. 1Q 2027: Revenue $30.97M, EPS $(0.75) — 10-Q Summary — source image
Decision brief

The 30-second read

$KMTSBearishMed
01

Why it matters

The earnings release provides fresh data for valuation models and risk assessment.

02

Market read

First‑report earnings for a micro‑cap health‑tech firm; informs short‑term trading decisions.

03

What to watch

Medicare supplier accreditation and expanding sales force may drive future profitability.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Kestra Medical Technologies filed its Q1 2027 10‑Q, detailing financial and operational highlights.

Company-level read

Ticker impact

$KMTSBearishMedium confidence
Context

Kestra Medical reported Q1 2027 results with $30.97M revenue (up 60% YoY) and a net loss of $44.09M, EPS $(0.75).

Expected impact

Potential downside of 5‑10% as investors digest the larger loss.

Evidence & confidence

Revenue growth is strong but the loss expansion signals cost issues; market may react negatively.

Market effects

Highlights challenges in the wearable cardiac defibrillator market despite revenue growth.

Limited to U.S. healthcare investors; no broader regional effect.

Minimal global impact given the company's small size.

Counterpoint

Strong revenue growth could outweigh short‑term loss, offering a buying opportunity if cost controls improve.

Key entities

  • Kestra Medical Technologies, LTD.

    Developer of the ASSURE® wearable cardiac defibrillator.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.